

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### SYNTHETIC PROCEDURE FOR THE PREPARATION OF NOVEL POTENT AND SELECTIVE A<sub>3</sub> ADENOSINE RECEPTOR RADIOLIGANDS

R. Volpini<sup>a</sup>; S. Costanzi<sup>a</sup>; C. Lambertucci<sup>a</sup>; S. Vittori<sup>a</sup>; G. Cristalli<sup>a</sup>

<sup>a</sup> Dipartimento di Scienze Chimiche, University of Camerino, Camerino, Italy

Online publication date: 31 March 2001

**To cite this Article** Volpini, R. , Costanzi, S. , Lambertucci, C. , Vittori, S. and Cristalli, G.(2001) 'SYNTHETIC PROCEDURE FOR THE PREPARATION OF NOVEL POTENT AND SELECTIVE A<sub>3</sub> ADENOSINE RECEPTOR RADIOLIGANDS', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 775 — 779

**To link to this Article:** DOI: 10.1081/NCN-100002428

**URL:** <http://dx.doi.org/10.1081/NCN-100002428>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## SYNTHETIC PROCEDURE FOR THE PREPARATION OF NOVEL POTENT AND SELECTIVE A<sub>3</sub> ADENOSINE RECEPTOR RADIOLIGANDS

R. Volpini, S. Costanzi, C. Lambertucci, S. Vittori, and G. Cristalli\*

Dipartimento di Scienze Chimiche, University of Camerino,  
I-62032 Camerino, Italy

### ABSTRACT

2-Phenylethynyladenosine and its N<sup>6</sup>-methyl derivative were synthesized and evaluated in binding assays at human adenosine receptors stably transfected on CHO cells. Results showed that the N<sup>6</sup>-methyl-2-phenylethynyladenosine is endowed with very high affinity and selectivity at A<sub>3</sub> receptor subtype. Hence, an alternative procedure for the synthesis of tritiated N<sup>6</sup>-methyl-2-phenylethynyladenosine was set up to introduce tritiated methylamine in the final step.

### INTRODUCTION


There is evidence that the purine nucleoside adenosine (Ado) specifically modulates neurotransmission through the activation of four receptor subtypes denominated: A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub> (1). Over the last few years many efforts have been directed toward discovery of potent and selective adenosine agonists. To this purpose we synthesized a number of adenosine-5'-N-ethyluronamide (NECA) derivatives substituted at the C-2-position with various (ar)alkynyl chains (2,3). Binding studies at human recombinant adenosine receptors (AdoRs) showed that the 2-alkynyl derivatives of NECA possess high affinity at the A<sub>3</sub> receptor subtype.

---

\*Corresponding author.

Moreover, the presence of different alkynes modulated the affinity of such derivatives at the other subtypes ( $A_1$ ,  $A_{2A}$ , and  $A_{2B}$ ). In particular, the 2-phenylethynyl-NECA (PENECA) was found to possess high affinity combined with good selectivity for  $A_3$  receptors (4) ( $K_i A_3 = 6.2$  nM; selectivity  $A_1/A_3 = 90$ , and  $A_{2A}/A_3 = 100$ ). Aimed at investigating the role of the ethylcarboxamido group in 5' position and to simplify the structure of this molecule we synthesized the corresponding adenosine analogue 2-phenylethynyladenosine (PEAdo, **4** (**5**), Scheme 1). Furthermore, a methyl group was introduced on the amine in 6 position of PEAdo to obtain **5**, since the presence of a substituent on the 6-amino group of adenosine and NECA drives the agonist affinity toward  $A_1$  and  $A_3$  receptors. The choice of a small substituent was due to the fact that the presence of a sterically hindered substituent, like an arylcarbonyl group, decreases the  $A_3$  receptor affinity of 2-alkynylNECA derivatives (6,7).

Preliminary binding studies at human AdoRs, stably transfected on CHO cells (8), showed that the 2-PEAdo (**4**) possesses good and comparable affinity at AdoRs in comparison to PENECA. The most exciting results were obtained with PEAdo (**5**), a compound endowed with high affinity and very high selectivity for  $A_3$  receptors. ( $K_i A_3 = 3.4$  nM; selectivity  $A_1/A_3 = 500$  and  $A_1/A_{2A} = 2500$ ). These findings prompted us to set up a different synthetic procedure for the synthesis of a new  $A_3$  radioligand.



Scheme 1.



## CHEMISTRY

The synthesis of 2-PEAdo (**5**) (**4**) and N<sup>6</sup>-methyl-2-phenylethynyladenosine (**5**) was carried out starting from 6-chloro-2-iodo-9-(2,3,5-tri-*O*-acetyl- $\beta$ -D-ribofuranosyl)-9H-purine (**1**) (**9**). Treatment of **1** with liquid ammonia or methylamine gave the derivatives **2** (**9**) or **3**, respectively. The alkyne in 2-position was introduced by reacting **2** or **3** with phenylethyne using a modification of the palladium catalyzed cross-coupling reaction (**10**) to give PEAdo (**4**) and N<sup>6</sup>-methylPEAdo (**5**) (Scheme 1).

Aimed at finding a convenient synthetic procedure for the preparation of radiolabelled N<sup>6</sup>-methyl-2-phenylethynyladenosine we coupled **1** with phenylethyne, using the cross-coupling reaction conditions, to obtain **6**. The 6-chlorine atom of **6** could be easily substituted by tritiated methylamine to give the corresponding radioligand of **5**. Unfortunately, reaction of **1** with phenylethyne did not give **6** but the disubstituted derivative **7**. An alternative synthetic route was designed to avoid the undesired disubstitution. Hence, 2-PEAdo (**4**) was used as the starting material. Reaction of this compound with diiodomethane and isopentyl nitrite gave the versatile synthon 2-phenylethynyl-6-iodoadenosine (**8**) from which the desired compound (**5**) was obtained by treatment with methylamine (Scheme 1). This procedure allows the introduction in the final step and with high yield of a tritiated methylamine, leading to potent and selective A<sub>3</sub> radioligand.

## CONCLUSION

The N<sup>6</sup>-methylPEAdo is the firstly reported adenosine derivative endowed with very high affinity and selectivity for A<sub>3</sub> adenosine receptor subtype.

The synthetic procedure to prepare the 6-iodo-2-phenylethynylAdo (**8**) could be a general synthetic method to obtain A<sub>3</sub> adenosine receptor radioligands, since the presence of an iodine atom at the C-6-position of 2-alkynyladenosines allows the introduction of tritiated amines in the final step.

## EXPERIMENTAL

Melting points were determined with a Büchi apparatus and are uncorrected. <sup>1</sup>H NMR spectra were obtained with Varian VXR 300 MHz spectrometer;  $\delta$  in ppm, *J* in Hz. All exchangeable protons were confirmed by addition of D<sub>2</sub>O. TLC were carried out on pre-coated TLC plates with silica gel 60 F-254 (Merck). For column chromatography, silica gel 60 (Merck) was used. Elemental analyses were determined on Carlo Erba model 1106 analyser and are within  $\pm 0.4\%$  of theoretical values.

**2-Iodo-N<sup>6</sup>-methyl-9-( $\beta$ -D-ribofuranosyl)adenine (**3**).** To compound **1** (1.86 mmol) methylamine (10 mL) was added and the reaction mixture was



allowed to stand at  $-20^{\circ}\text{C}$  for 1 h. The exceeding amine was evaporated and the residue was chromatographed on a silica gel column eluting with  $\text{CHCl}_3$ -MeOH (93:7) to give **3** (634 mg; 69%) as amorphous solid;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  2.92 (d, 3H,  $J = 4.1$  Hz,  $\text{NH}-\text{CH}_3$ ), 3.61 (m, 2H,  $\text{CH}_2-5'$ ), 3.95 (m, 1H, H-4'), 4.14 (m, 1H, H-3'), 4.53 (m, 1H, H-2'), 5.82 (d, 1H,  $J = 6.1$  Hz, H-1'), 8.14 (d, 1H, NH), 8.31 (s, 1H, H-8). Anal. ( $\text{C}_{11}\text{H}_{14}\text{IN}_3\text{O}_4$ ) C, H, N.

**Cross-coupling reaction for the synthesis of 5 and 7.** To a solution of **3** or **1** (0.51 mmol) in dry DMF (15 mL), and  $\text{Et}_3\text{N}$  (2.3 mL) under an atmosphere of  $\text{N}_2$  were added bis(triphenylphosphine)palladium dichloride (8.1 mg, 0.012 mmol) and CuI (0.51 mg, 0.003 mmol). The phenylethyne (3.1 mmol) was added and the reaction mixture was stirred under an atmosphere of  $\text{N}_2$  at room temperature for the time reported for each compound. The solvent was removed *in vacuo* and the residue was chromatographed on a silica gel column eluting with a suitable mixture of solvents to give **5** or **7** as amorphous solids:

**$\text{N}^6$ -Methyl-2-(phenylethyn-1-yl)-9-( $\beta$ -D-ribofuranosyl)adenine (5).** The reaction of **3** with phenylethyne for 16 h, followed by chromatography on a silica gel column eluting with  $\text{CHCl}_3$ -MeOH (92:8), gave **5** (120 mg; 84%), after crystallization from EtOH.

The same compound was also obtained by reacting **8** (0.15 mmol) with methylamine (2 mL) at  $5^{\circ}\text{C}$  for 5 h. After removing the exceeded methylamine the residue was chromatographed on flash silica gel column eluted with  $\text{CHCl}_3$ - $\text{cC}_6\text{H}_{12}$ :MeOH (87:10:3) to give **5** (42 mg; 73%); mp  $229-231^{\circ}\text{C}$ ;  $^1\text{H}$  NMR ( $\text{Me}_2\text{SO}-d_6$ )  $\delta$  2.99 (br s, 3H,  $\text{NH}-\text{CH}_3$ ), 3.64 (m, 2H,  $\text{CH}_2-5'$ ), 3.98 (m, 1H, H-4'), 4.15 (m, 1H, H-3'), 4.57 (m, 1H, H-2'), 5.93 (d, 1H,  $J = 6.2$  Hz, H-1'), 7.47 (m, 3H, H-Ph), 7.65 (m, 2H, H-Ph), 8.07 (m, 1H, NH), 8.47 (s, 1H, H-8). Anal. ( $\text{C}_{19}\text{H}_{19}\text{N}_5\text{O}_4$ ) C, H, N.

**2,6-(Diphenylethyn-1-yl)-9-(2,3,5-tri-O-acetyl- $\beta$ -D-ribofuranosyl)purine (7).** The reaction of **1** with phenylethyne for 24 h, followed by chromatography on a silica gel column eluted with  $\text{CHCl}_3$ - $\text{cC}_6\text{H}_{12}$ -MeCN (52:40:8) gave **7** (293 mg; 51%) as amorphous solid;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  2.04 (s, 3H,  $\text{COCH}_3$ ), 2.08 (s, 3H,  $\text{COCH}_3$ ), 2.15 (s, 3H,  $\text{COCH}_3$ ), 4.39 (m, 3H,  $\text{CH}_2-5'$  and H-4'), 5.74 (m, 1H, H-3'), 6.00 (m, 1H, H-2'), 6.40 (d, 1H,  $J = 5.3$  Hz, H-1'), 7.57 (m, 6H, H-Ph), 7.74 (m, 6H, H-Ph), 8.99 (s, 1H, H-2). Anal. ( $\text{C}_{32}\text{H}_{26}\text{N}_4\text{O}_7$ ) C, H, N.

**6-Iodo-2-(phenylethyn-1-yl)-9-( $\beta$ -D-ribofuranosyl)adenine (8).** To a solution of **4** (0.27 mmol) in dry DMF (2 mL) diiodomethane (3.61 mL) and isopentyl-nitrite (1.12 mL) were added and the mixture was heated at  $60^{\circ}\text{C}$  for 30'. The solvent was evaporated and the residue was chromatographed on a silica gel column eluted with  $\text{CHCl}_3$ - $\text{cC}_6\text{H}_{12}$ -MeOH (83:10:7) to give **7** (120 mg; 33%) as amorphous solid;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  3.68 (m, 2H,  $\text{CH}_2-5'$ ), 4.01 (m, 2H, H-4'), 4.20 (m, 1H, H-3'), 4.55 (m, 1H, H-2'), 6.03 (d, 1H,  $J = 5.2$  Hz, H-1'), 7.53 (m, 3H, H-Ph), 7.73 (m, 2H, H-Ph), 9.00 (s, 1H, H-8). Anal. ( $\text{C}_{18}\text{H}_{15}\text{IN}_4\text{O}_4$ ) C, H, N.



### ACKNOWLEDGMENTS

Supported by EC Contract No BMH4-98-3474 and by a grant from the University of Camerino (Fondo di Ricerca di Ateneo).

### REFERENCES

1. Ralevic, V.; Burnstock, G. *Pharmacol. Rev.* **1998**, *50*, 413–492.
2. Cristalli, G.; Volpini, R.; Vittori, S.; Camaioni, E.; Monopoli, A.; Conti, A.; Dionisotti, S.; Zocchi, C.; Onigini, E. *J. Med. Chem.* **1994**, *37*, 1720–1726.
3. Cristalli, G.; Camaioni, E.; Vittori, S.; Volpini, R.; Borea, P. A.; Conti, A.; Dionisotti, S.; Onigini, Monopoli, A.; *J. Med. Chem.* **1995**, *38*, 1462–1472.
4. Cristalli, G.; Camaioni, E.; Costanzi, S.; Vittori, S.; Volpini, R.; Klotz, K.-N. *Drug Dev. Res.* **1998**, *45*, 176–181.
5. Abiru, T.; Miyashita, T.; Watanabe, Y.; Yamaguchi, T.; Machida, H.; Matsuda, A.; *J. Med. Chem.* **1992**, *35*, 2253–2260.
6. Baraldi, P. G.; Cacciari, B.; Pineda de Las Infantas, M. J.; Romagnoli, R.; Spalluto, G.; Volpini, R.; Costanzi, S.; Vittori, S.; Cristalli, G.; Melman, N.; Park, K.; Ji, X.; Jacobson, K. A. *J. Med. Chem.* **1998**, *41*, 3174–3185.
7. Volpini, R.; Camaioni, E.; Costanzi, S.; Vittori, S.; Klotz, K.-N.; Cristalli, G.; *Nucl. & Nucl.*, **1999**, *18*, 2511.
8. Klotz, K.-N.; Hessling, J.; Hegler, J.; Owman, B.; Kull, B.; Fredholm, B.B.; Lohse M. J. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1998**, *357*, 1–9.
9. Nair, V.; Richardson, S. G.; *Synthesis* **1982**, 670–672.
10. Cristalli, G.; Eleuteri, A.; Vittori, S.; Volpini, R.; Lohse M. J.; Klotz, K.-N.; *J. Med. Chem.* **1992**, *35*, 2363–2368.



## **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

**[Order now!](#)**

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002428>